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Abstract: Women with renal disease, besides many dysfunctions, face increasing infertility and high-risk pregnancy due to uremia and changes 
of the hormonal functions. After renal transplantation, sexual dysfunction improves, providing the possibility of successful pregnancy for 
women of childbearing age. However, kidney transplanted patients are high-risk pregnant patients with increased maternal and fetal risks, 
and the graft also may be compromised during pregnancy; most studies report on several successive deliveries due to multidisciplinary team 
management. In clinical practice, the graft is rarely aff ected during the period of gestation. Fetal development disorders are also rare although 
preterm delivery and intrauterine growth retardation are common. For now, several studies and clinical investigations proved that, under 
multidisciplinary control, kidney transplanted female patients are also possible to have safe pregnancy and successful delivery. There are 
conﬂ icting data in the literature about the prevention of complications and the timing of pregnancy. Herein, we would like to present some 
experience of our centre. A total of 847 kidney transplantations have been performed between June 1993 and December 2013 with 163 
childbearing aged females (18–45 years) in our center. We report on three kidney transplanted patients who have given birth to healthy 
newborns. In our practice, severe complications have not been observed.
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Introduction
Female patients suff ering from chronic uremia often ex-
perience infertility due to multifactorial etiology. The 
loss of positive feedback from estradiol results in the ab-
sence of the typical preovulatory pituitary gonadotropin 
lutenizing hormone (LH) surge. Besides, there is hyper-
prolactinaemia due to autonomous hypersecretion [1, 
2]. Within 12 months after renal transplantation, sexual 
dysfunction improves; the patients become ovulatory 
and the menstruation resumes. Transplantation off ers a 
better quality of life providing the possibility of success-
ful pregnancy for women of childbearing age. However, 
kidney transplant recipients are high-risk pregnant pa-
tients with increased maternal and fetal risks, and the 
graft also may be compromised [3] (Table I). Several 
clinical case reports have been published, stating that 
pregnancy does not seem to have adverse eff ects either 
on long-term graft or patient survival or renal function 
in women after renal transplantation. Fetal develop-
ment disorders are also rare, though preterm delivery 
and intrauterine growth retardation are common [4]. 
Preconception counseling and timing of pregnancy are 
of high importance in the case of kidney transplanted 
patients. The data about these issues are controversial in 
the literature; the most often applied recommendations 
are summarized in Table II. Before conception, the level 
of immunosuppression should be reduced [5]. To avoid 
acute rejections, drug level should be monitored closely 
and the dosage should be modiﬁ ed to reach the recom-
mended target level. Because of their teratogenic eff ect, 
mycophenolate mofetil (MMF) and sirolimus (SRL) are 
contraindicated; they should be withdrawn 6 weeks be-
fore planned conception. Gravid uterus may obstruct 
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the graft ureter (mass eff ect); however, it is a rarely re-
ported cause of allograft dysfunction in pregnancy [6]. 
In our center, 847 patients suff ering from end stage re-
nal disease have been transplanted till December 2013, 
among them 163 women of childbearing age out of 269 
female patients. Three patients have decided to become 
pregnant until that time.
Case Report
Our ﬁ rst patient is a 39-year-old female renal transplant 
recipient with a history of end stage renal disease due to 
chronic glomerulonephritis and chronic pyelonephritis 
diagnosed in 1995. She was on hemodialysis for 3 years, 
and then, she had a cadaver transplant. During dialy-
sis, she got infected with hepatitis C virus (HCV). Six 
years after transplantation, she delivered a normal weight 
healthy male newborn by Cesarean section in 2001. Pre-
conceptionally, she was on triple therapy: cyclosporine A 
(CsA), methylprednisolone, and azathioprine. Six weeks 
before conception, azathioprine and methylpredniso-
lone were withdrawn and the dose of CsA was reduced 
(150–175 mg/day). During pregnancy, the serum level 
of CsA was between 150 and 200 ng/mL (C0). Right 
after delivery, the dose of CsA was raised up to 200–225 
mg/day (C0: 200–260 ng/mL), and 32 mg/day meth-
ylprednisolone was given for 3 days and then tapered 
to 4 mg/day. The renal function of the recipient con-
tinued to be stable after delivery. Before pregnancy, we 
found blood serum creatinine levels 119–125 μmol/L 
permanently; however, during pregnancy, a moderate 
elevation has been observed (Table III). Despite good 
graft function the patient’s compliance has become in-
Table I Kidney transplanted patients increased risk factors in pregnancy
Maternal complications Fetal complications
1. Hypertension 1. Pregnancy loss (mainly I., II. trimester)
2. Preeclampsia 2. Preterm delivery
3. Allograft rejection 3. Intrauterine growth retardation (IUGR)
4. Infections
5. Diabetes
Table II Criteria for considering pregnancy in renal transplant recipients
1. Good general health at least 2 years after transplantation
2. Absence of other contraindications (obstetrics, etc.)
3. Stable allograft function — serum creatinine below 180 μmol/L (2 mg/dL)
4. No recent episodes of acute rejection, no evidence of ongoing rejection
5. Normal blood pressure (below 140/90 mmHg) or minimal antihypertensive regimen (one drug)
6. Absence of or minimal proteinuria (<0.5 g/day)
7. No sign of pelvicalyceal distension (abdominal ultrasound)
8.  Recommended immunosuppression:
  Prednisone <15 mg/day
  Azathioprine <2 mg/kg/day
  CsA or tacrolimus at therapeutic levels (according to blood serum level)
  Close drug level monitoring
  MMF and sirolimus are contraindicated because of their teratogenic effect
  MMF and sirolimus should be stopped at least 6 weeks before planned conception is attempted
Table III Comparison of selected nephrological parameters of our kidney transplanted patients with pregnancy
1st Patient 2nd Patient 3rd Patient
Age at the time of pregnancy (year) 39 30 31
Serum creatinine levels 6 weeks before
planned conception (μmol/L) 119–125 160–175 111–115
Serum creatinine levels during pregnancy (μmol/L)  116–140 164–174 93–110
Acute rejection observed during pregnancy No No No
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suffi  cient from 2005. By reason of that condition after 
several therapeutic approaches, we were forced to refer 
back her to the hemodialysis program in 2008. Graft-
ectomy was performed in 2009 because of chronic al-
lograft rejection.
Our second patient is a 30-year-old renal transplant 
recipient with end stage renal disease because of chronic 
glomerulonephritis, diagnosed as infant. She has hy-
pertension in her history. She was not dialyzed before 
transplantation. She had complaints about severe left hip 
joint pain; the investigation performed showed avascular 
necrosis in the head of the femur. Core decompression 
was performed in 2000, and her complaints decreased 
permanently. Two years after surgery without any com-
plications, she got ovulatory induction treatment, since 
spontaneous ovulation did not start. She had extrauter-
ine gravidity – a possible complication of this therapy, 
and a laparoscopic salpingotomy was performed. Two 
years later, she got pregnant again and she delivered on 
the 28th week her premature baby per vias naturales as a 
result of preterm membrane rupture. The weight of the 
male newborn was 990 g. She was on triple therapy be-
fore the pregnancy: CsA, methylprednisolone, and MMF. 
Six weeks before conception, methylprednisolone and 
MMF were withdrawn and dose of CsA was decreased 
to 75–100 mg/day (C2 700–900 ng/ mL). Right after 
delivery, CsA dosage was increased to 150–175 mg/ day 
(C2 1100–1300 ng/mL), 32 mg/day methylpredniso-
lone, and 500 mg/day MMF was given. There was a 
moderate elevation in the serum level parameters during 
pregnancy comparing to preconceptionally but the graft 
function was stable.
Our third patient is a 31-year-old female who suff ered 
from end stage renal disease as a consequence of chronic 
glomerulonephritis. She was on dialysis for 1 year, when 
she got pregnant in 1996 and delivered a male preterm 
newborn by Cesarean section. Seven years later she got 
a kidney transplant in 2003. Two years later, she got in-
tracranial bleeding in the thalamus. Two years later, she 
had transitory ischemic attack. She recovered fully. Two 
years later with stable graft function and good general 
health, she decided to become pregnant again. Medi-
cations were modiﬁ ed according to the international 
guidelines. However, she got pregnant only 2 weeks af-
ter decreasing dosage of CsA and methylprednisolone 
and withdrawal of MMF. Artiﬁ cial abortion was off ered 
because of the high teratogenic eff ect, but she refused it. 
Her fetus suff ered missed abortion on the 6th week, and 
the abortion was terminated. There were no maternal 
complications. Then after half a year, she got pregnant. 
In March 2009, the patient, due to preterm membrane 
rupture, underwent a Cesarean section giving live birth 
to her 1300 g preterm male infant on the 30th week 
of pregnancy, with no congenital malformation. Be-
fore conception, she was on CsA 50–75 mg/day (C2 
360–500 ng/mL) and methylprednisolone 4 mg/day, 
and MMF was withdrawn. After delivery, higher dose 
immunosuppression was given with CsA 50–75 mg/day 
(C2 500–600 ng/mL), methylprednisolone 4 mg/day, 
and MMF 2 × 500 mg/day. Similarly to the two other 
patients, we found mild elevation in the serum levels of 
creatinine during pregnancy.
Discussion
Renal transplantation has provided for women of child-
bearing age not only better quality of life but increased 
fertility and the possibility of successful pregnancy out-
comes. However, kidney transplanted patients are high-
risk pregnant patients with signiﬁ cant maternal, fetal, 
and allograft complications, due to multidisciplinary 
control they can give life to healthy infants [2, 3]. If the 
pregnancy extends beyond the ﬁ rst trimester, it has high 
probability of reaching full term [7]. One of the main 
maternal complication during gestation is hypertension 
as a result of either preexisting chronic hypertension or 
development of new onset hypertension during gesta-
tion [8]. Patients with well-balanced blood pressure are 
more likely to have succesfull delivery with healthy new-
borns and less likely to have maternal or fetal complica-
tions [9]. According to some major investigations, blood 
pressure is lowest in the ﬁ rst trimester during normal 
gestation and slowly elevates in late gestation. Similar 
but blunted pattern of blood pressure progression was 
often observed in the case of transplant recipient preg-
nant females [10]. Methyldopa was recommended by 
several studies for mild hypertension management, since 
it is well-tolerated and, moreover, does not alter utero-
placental or fetal hemodynamics. According to novel re-
comendations for urgent blood pressure control, hydral-
azine, labetolol, or nifedipine has been considered [11]. 
It is highlighted that angiotensin-converting enzyme in-
hibitors and angiotensin receptor blockers are absolutely 
contraindicated in pregnancy because of adverse fetal ef-
fects, and atenolol must be also avoided because of con-
cerns about fetal growth found by major studies [12]. 
Renal transplant pregnant patients with hypertension 
are at increased risk for development of superimposed 
preeclampsia, with an incidence of 15 to 25% compared 
with 5% of normotensive pregnancies [13]. The inci-
dence of acute rejection is low as found by several inves-
tigations [14]. Generally, pregnancy does not seem to 
have any adverse eff ect on the long-term graft survival of 
renal allografts [15]. If there is a suspicion of acute rejec-
tion based on clinical signs and symptoms, it has to be 
conﬁ rmed by ultrasound guided core biopsy. In the case 
of acute rejection, it is prudent to initial treatment with 
steroid. There are limited data for the use of other agents 
such as anti-T-lymphocyte antibodies, muromonoab-
CD3, and antithymocyte globulin in the case of allograft 
rejection, but IVIG appears to be safe [2]. Considering 
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the creatinine levels, we found relatively constant serum 
levels in the case of all our three patients.
The applied immunosuppressive drugs have many 
side eff ects, without limited information about their in-
ﬂ uence on the fetus. It is recommended to give the mini-
mal eff ective dose. On the basis of some investigations, 
one-year-long period between renal transplantation and 
conception seems reasonable to stabilize renal function 
and reduce immunosuppressant drug doses [16]. Breast 
feeding is not considered to be absolutely contraindi-
cated; however, immunosuppressants cross the placenta 
and appear in the breast milk to varying degrees [17]. 
In our clinical practice, we do not suggest breast feeding 
to the patients at all. Preconceptionally (at least 6 weeks 
before planned conception), MMF should be with-
drawn or switched to azathioprine. During pregnancy, 
it is enough to apply decreased dose of immunosuppres-
sants, although inadequate medication can cause acute 
rejection. Right after delivery, elevated immunosuppres-
sion needed and supplemented with the drugs previ-
ously interrupted. In the case of our third patient’s ﬁ rst 
pregnancy after transplantation, there was not enough 
period of time between the modiﬁ cation of immunosup-
pression and the conception and, later, it was terminated 
as a missed abortion. Outcomes of unwanted pregnan-
cies are inferior to those for planned pregnancies [18]. 
Congenital malformations are rare although preterm de-
livery and intrauterine growth retardation are common. 
Fetal and maternal complications (Table I) even can lead 
to more serious complications [19, 20]. Pregnancy does 
not appear to have adverse eff ects on long-term graft or 
patient survival or kidney function in women after renal 
transplantation [4]. The fact that transplantation alone 
does not have any eff ect on the way of delivery, cesarean 
section is not obligatory (Tables III and IV ).
Considering the international guidelines and recom-
mendations, tailored therapy should be applied to every 
kidney transplanted patient. Adequate preconceptional 
counseling and right timing of conception can give a 
real opportunity for kidney transplanted patients to give 
birth to healthy children. In Hungary, until October 
2011, 3.9% of renal and 14.3% of liver transplanted fer-
tile women gave birth to children; however, there was no 
pregnancy among heart, lung, and pancreas recipients. 
All of the newborns were healthy, and there was no acute 
rejection episode or graft loss due to pregnancy [21]. 
Although, in our center, numerous kidney transplanta-
tions were performed with low number of delivery, it 
seems safe to manage pregnancy under multidisciplinary 
medical control.
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